Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q2 EPS of ($0.52), $0.05 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $77.8 million versus the consensus estimate of $75.2 million.

GUIDANCE:

Mirum Pharmaceuticals, Inc. sees FY2024 revenue of $310-320 million, versus the consensus of $312.7 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.